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Managing diabetes at the end of life 
L ife expectancy has increased in the past 20 years including for people with diabetes, but diabetes 
is among the top ten leading causes of 
death in Australia, primarily due to long 
term complications. The focus of palliative 
care, especially at the end of life, is on 
maintaining comfort and quality of life 
by controlling unpleasant symptoms, 
managing pain and providing spiritual 
and other support to the individual and 
his or her family including helping them 
make infmmed decisions about care. 
PALLIATIVE AND OF LIFE CARE 
The Australian Government adopted 
the World Health Organisation (WHO) 
definition of palliative care in the National 
Palliative Care Strategy {2010). 1 
An approach that improves the quality 
of life of patients and their families facing 
the problems associated with life-threatening 
illness, through prevention and relief of 
suffering by means of early identification and 
impeccable assessment and treatment of pain 
and other problems, physical, psychosocial 
and spirituaF. 
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Managing diabetes at the end of life 
is complex and there is limited evidence 
about what constitutes best practice 
diabetes care at the end of life. However, 
consensus guidelines3 and an Ethical 
Framework for Integrating Palliative Care 
Principles into the Management of Advanced 
Chronic or Terminal Conditions' are 
available to guide clinical decisions. 
Dying is a complex process that 
follows a common continuum from 
stable through unstable, deteriorating 
and terminal stages and usually lasts 
6-12 months5 . However, the stages 
usually do not occur in a linear fashion, 
especially in diabetes where there may 
be a long progression to terminal care 
and many episodes of stable/unstable 
diabetes before the indi\-idual enters the 
deteriorating and terminal stages. 
Thus, it can be difficult to determine 
an individual's disease trajectory and 
prognosis and consequently, to decide 
when to begin discussing palliative 
and end of life care and advanced care 
planning with people with diabetes. 
However, p roactive care planning is 
possible. Regular consultations and 
annual complication assessments, 
which are part of standard diabetes care, 
represent opportunities to identify the 
need to consider palliative care issues 
such as advanced care planning, power of 
attorney and other documentation. 
DIABETES AND END OF LIFE CARE 
A p lethora of physiological and 
psychological factors affect glycaemic 
control during end of life care. The 
contribution of hyperglycaemia and 
hypoglycaemia to discomfort, pain and 
unpleasant symptoms is largely under-
recognised, particularly if regular blood 
glucose (BG) monitoring is not part of 
the care plan. Many palliative health 
professionals regard BG monitoring as 
burdensome, distressing and in conflict 
with palliative care philosophy, rather than 
a useful diagnostic tool to detect hypo-
and hyperglycaemia and aid decisions 
about symptom control and comfort. 
In contrast, most people with diabetes 
and their families regard BG monitoring 
as comforting and essential to optimising 
their care, except in the last hours of life3• 
KEY MANAGEMENT 
CONSIDERATIONS 
Diabetes management should be 
integrated into the overall palliative care 
plan. In addition, corticosteroid-induced 
hyperglycaemia is common in palliative 
care situations especially in people with 
pre-existing diabetes risk factors. 
THE CARE PLAN NEEDS TO 
INCLUDE MAKING PROVISION FOR: 
• Identifying individuals at risk of 
steroid-induced diabetes when 
people are admitted to palliative care 
and/or when steroid medications are 
prescribed. 
• Managing diabetes that develops 
following steroid use or a diagnosis 
of cancer. 
• Identifying and managing pre-
existing diabetes and diabetes 
complications that affect management 
decisions such as medications when 
renal and liver disease are present 
care; however, managing existing 
complications to reduce pain and promote 
comfort is essential. 
Opinions differ about the optimal 
BG target range and BG monitoring 
and can contribute to pain and frequency. The conservative approach 
discomfort. to BG monitoring and treating 
• Managing hypoglycaemia, which can hyperglycaemia in palliative care 
be individually or collectively related situations is changing as health 
to hypoglycaemic medications, low professionals recognise the impact of 
hepatic glucose reserves, particularly hyperglycaemia on comfort and quality 
if the individual is malnourished of life and safer more effective treatments 
or has hepatic metastases, renal are available. In addition, hypo- and 
impairment or gastrointestinal hyperglycaemia can be difficult to detect 
disturbance due to anorexia and without BG monitoring because many 
( ( of the symptoms 
As in all diabetes care planning, can have multiple 
glycaemic targets need to be contributory causes 
and can be present 
individualised to ensure safety, comfort J J 
and avoid hypo-and hyperglycaemia. 
without significant 
symptoms. 
Hyperglyca emia 
cachexia syndrome. causes distressing osmotic symptoms, 
no BG monitoring as staff 'giving up' 8 . 
TYPE 1 DIABETES 
Diabetes management depends on the 
prognosis, oral intake and co-existing 
diseases as well as the type of diabetes. 
People with type 1 diabetes who are 
reasonably well should continue their 
usual insulin regimens but doses 
should be adjusted to avoid hypo and 
hyperglycaemia and in the terminal phase. 
Generally, long acting insulin analogues 
or small doses of rapid acting insulin 
might be appropriate if the person has 
nausea and vomiting or little appetite. In 
the future, there may be a role for insulin 
pumps. 
Blood ketone tests should be 
performed if the BG is consistently over 
15 mmol!L, especially if the individual 
has nausea, vomiting and signs of 
dehydration. 
• Choosing a safe, effectiYe medication 
regimen to maintain BG in an 
acceptable range. Renal and 
hepatic function is often altered 
and gastrointestinal disturbance 
and impaired glucose absorption 
is common, which, along with the 
prognosis and the individual's care 
decisions, influences medication 
choices. Many oral hypoglycaemic 
agents might be contraindicated and 
insulin might be a safer more easily 
adjusted option. 
exacerbates pain, contributes to delirium TYPE 2 DIABETES 
• Activating the Liverpool Care 
Pathway when the interdisciplinary 
team agrees the individual is dying<. 
Significantly, care is likely to change 
as the individual's health status changes 
within the Palliative Care Outcomes 
Collaborative (PCOC) (2008) 5 stages, 
and the care plan may need to be revised 
frequently before the Liverpool Care 
Pathway applies. 
GLYCAEMIC TARGETS 
Preventing long term diabetes 
complications is not a priority of palliative 
and confusion, reduces mood, problem - Sulphonylureas (SU) doses may need to 
solving and coping ability and quality of be reduced to avoid hypoglycaemia. SU 
life. Thus, preventing hyperglycaemia can may be contraindicated if renal and/or 
enhance comfort and meet a key palliative liver disease is present. Side effects such as 
care goal. gastrointestinal symptoms associated with 
Hypoglycaemia risk is increased in 
people with diabetes on sulphonylureas 
and/or insulin. The risk of hypoglycaemia 
is increased in palliative situations due 
to anorexia, malnourishment, liver 
disease, low glycogen stores and cachexia 
syndrome in advanced cancer. As in 
all diabetes care planning, glycaemic 
targets need to be indi\idualised to 
ensure safety, comfort and avoid hypo-
and hyperglycaemia. Generally, a blood 
glucose range from 5-15 mmol/L will 
achieve these aims. 
BLOOD GLUCOSE MONITORING 
Many people with diabetes and their 
families want to continue their usual 
BG monitoring regimen because it 
helps them maintain stability at a 
frightening, uncertain time of life3· 7. In 
addition, some people with diabetes 
and/or their families regard reduced or 
Metformin also needs to be considered 
and metformin should be ceased if there 
is renal failure (eGFR <30ml!min). Short 
acting insulin or long acting insulin 
analogues may be a suitable alternative 
to oral hypoglycaemic agents depending 
on the individual's physiological status, 
symptoms and comfort. 
Thiazolididones may not be suitable 
if liver and cardiovascular disease is 
present. The GLP-1 and DPP-1V may be 
an alternative but have not been tested 
in palliative care settings. In addition, 
the GLP-1 often cause nausea and both 
types of agents have been associated \-\lith 
pancreatitis. 
CORTICOSTEROID-INDUCED 
DIABETES 
Corticosteroids reduce insulin sensitivity 
and increase insulin resistance 
proportional to the dose of steroid and 
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duration of use9• Non-diabetic individuals Blood glucose monitoring provides 
have different thresholds for developing important information on which to base 
diabetes. The presence of diabetes risk 
factors increases the risk. Screening people 
for diabetes risk factors on admission 
to palliative care and monitoring blood 
glucose levels when people commence 
steroids will identify steroid -induced 
hyperglycaemia and enable treatment to 
be commenced to reduce the impact on 
comfort, cognitive function and pain. 
Steroid medications usually increase 
blood glucose levels during the day 
especially post prandially and the blood 
glucose tends to normalise overnight 
and may be in the normal range before 
breakfast. The most effective management 
is to monitor blood glucose levels 
especially in the afternoon, use the lowest 
effective steroid dose for the shortest 
possible time and proactively treating 
hyperglycaemia, e.g. with a morning 
dose of long acting insulin tJ or Premixed 
insulin with breakfast. However, the 
insulin regimen should be guided by the 
blood glucose pattern. 
EDUCATION 
Education and support, including 
bereavement support is essential for 
individuals with diabetes, their families 
aJ:C)d often health professional carers. 
Sensitive discussion about the need to 
adjust medicmes and other changes to 
established self-management routines is 
essential. In addition, diabetes specialists 
are in an ideal position to identify regular 
opportunities to identify when to begin 
discussing palliative care and other end of 
life issues. 
SUMMARY 
Caring for people at the end of life is an 
important part of the continuum of care. 
Health professionals have a responsibility 
to advise and support people with 
diabetes to make timely decisions about 
their diabetes care at the end of life. 
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treatment decisions. The aim should be to 
avoid hypo and hyperglycaemia. 
The individual's wishes and 
accumulated diabetes knowledge and 
expertise should be respected and 
acknowledged. 
} 
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KEY PRACTICE POINTS 
!!l Palliative care focuses on 
avoiding burdensome 
monitoring, managing 
unpleasant symptoms, 
comfort and quality of life 
through interdisciplinary 
team care. 
[!] It is essential that the 
individual and his or her 
family are involved in care 
decisions. 
!!l Palliative care is a key 
aspect of the chronic 
disease trajectory. Proactive 
planning for palliative 
situations could be 
incorporated into annual 
diabetes complication 
screening processes. 
[!] Hyper- and hypoglycaemia 
contribute to the distressing 
symptoms associated with 
end of life care but their 
presence and significance is 
often under-recognised and 
under-rated. 
[!] Blood glucose monitoring 
can help identify hypo- and 
hyperglycaemia and enable 
appropriate treatment. 
!!l The blood glucose range 
and medication regimen 
should be individualised and 
adjusted as needed. 
Prof. Trisha Dunning 
AM 
Chair in Nursing and 
Director Centre for 
Nursing and Allied 
health Research Deakin 
University and Barwon 
Health, GeelongVictoria 
